Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

Janssen, a pharmaceutical company of Johnson & Johnson, established more than 99 sites across the globe to enroll the more than 716 patients needed for the study. Synexus, which is the largest multi-national company entirely focused on the recruitment and running of clinical trials at its own dedicated research centers, exceeded its recruitment target by more than 50% at its Watermeyer site in Pretoria.

Synexus country manager Dr. Sanet Aspinall commented, “We are often able to exceed our pharma and CRO client’s expectations as we have a very effective enrollment team to recruit patients from the large pool of people surrounding our research centers. This team has developed a sophisticated outreach program which works closely with GPs, primary care clinics and public hospitals in order to find the right patients quickly.”

Linda Roach, the GCO country manager of Janssen Pharmaceuticals in South Africa said, “Within our regulatory environment here in South Africa, we need to partner with sites that can enroll quickly with quality data and can support our efforts to achieve our recruitment targets. Synexus Watermeyer site in Pretoria is one such site."

"This is of particularly importance in South Africa as regulatory timelines can be slow leaving a shorter time frame in which to find these patients. Selection of the right site and infrastructure for this study has proven that, the country can not only deliver but exceed the target number of patients,” Roach continued.

Share:          
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs